Zobrazeno 1 - 10 of 41 pro vyhledávání: '"Katja M. Fagerlund"'
1
Abstract 2481: Human osteoclast assays for studying the effects of bone metastasis treatments with different mechanisms of action
Autor: Katja M. Fagerlund, Mervi Ristola, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jukka P. Rissanen
Publikováno v: Cancer Research. 83:2481-2481
Metastasis to bone is one of the common complications associated with different types of advanced cancer. Zoledronic acid, a third generation nitrogen containing bisphosphonate, accumulates in bones where it binds to hydroxyapatite crystals. For year
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b8538e7421f3032e0f621c4bc85b7783
https://doi.org/10.1158/1538-7445.am2023-2481
Zobrazit plný text záznamu
2
Abstract 49: Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer
Autor: Mari I. Suominen, Justyna Zdrojewska, Yvonne Konkol, Katja M. Fagerlund, Mervi Ristola, Jukka P. Rissanen
Publikováno v: Cancer Research. 83:49-49
Oncology drug development has markedly lower success rate (3.4%) than other indications (20.9%) as reported by Wong, Siah and Lo in 2019. Animal models are often pointed at as the culprits for failure in clinical trials. While better animal models fo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc1836f155babc3a348f8734bb86b68d
https://doi.org/10.1158/1538-7445.am2023-49
Zobrazit plný text záznamu
3
Abstract 1624: Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro
Autor: Jenni H. Mäki-Jouppila, Jukka P. Rissanen, Katja M. Fagerlund
Publikováno v: Cancer Research. 82:1624-1624
Direct effects of cancer therapeutics on immune cell activity can be challenging to determine on system level in vivo. Therefore, it is important to develop and discover novel ways to study the effects of immune cells on cancer cells using also in vi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9869e6a7ed19b5b948bc0c900d4adb3
https://doi.org/10.1158/1538-7445.am2022-1624
Zobrazit plný text záznamu
4
Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
Autor: Dominik Mumberg, Anniina Luostarinen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Katja M. Fagerlund, Birgitta Sjöholm, Jukka P. Rissanen, Sanna-Maria Käkönen, Gerhard Siemeister, Arne Scholz, Anna Huhtinen, Esa Alhoniemi
Publikováno v: International Journal of Molecular Sciences, Vol 22, Iss 5570, p 5570 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 11
Osteolytic bone disease is a hallmark of multiple myeloma (MM) mediated by MM cell proliferation, increased osteoclast activity, and suppressed osteoblast function. The proteasome inhibitor bortezomib targets MM cells and improves bone health in MM p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc64c584fab49eaba12f8fc70a0b90a4
https://www.mdpi.com/1422-0067/22/11/5570
Zobrazit plný text záznamu
7
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Autor: Esa Alhoniemi, Karl Ziegelbauer, Mari I. Suominen, Arne Scholz, Salla K. Laine, Robert L. Vessella, Eva Corey, Yvonne Konkol, Sanna-Maria Käkönen, Dominik Mumberg, Jukka P. Rissanen, Jussi M. Halleen, Jukka P. Morko, Z. Peng, Katja M. Fagerlund
Publikováno v: Clinical Cancer Research. 23:4335-4346
Purpose: Radium-223 dichloride (radium-223, Xofigo), a targeted alpha therapy, is currently used for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases. This study examines the mode-of-action and antitumor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae26aabb24b7fcce73898f1ef3fa3a1
https://doi.org/10.1158/1078-0432.ccr-16-2955
Zobrazit plný text záznamu
8
Abstract 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro
Autor: Katja M. Fagerlund, Jussi M. Halleen, Jenni H. Mäki-Jouppila
Publikováno v: Cancer Research. 80:2759-2759
Immuno-oncology has emerged as one of the most promising new approaches in cancer drug development. Greater cancer cell specificity of treatments can be achieved when the immune cells of a patient are used against tumors. Therefore, it is important t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20eb6d16b1d5727a99112eef7ca85c92
https://doi.org/10.1158/1538-7445.am2020-2759
Zobrazit plný text záznamu
9
Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer
Autor: Justyna Zdrojewska, Mari I. Suominen, Katja M. Fagerlund, Jussi M. Halleen, Jenni Bernoulli, Johann Zimmermann
Publikováno v: Cancer Research. 79:2007-2007
Metastatic breast cancer (MBC) is the most advanced stage of breast cancer, diagnosed as stage IV. Typically, MBC metastases occur in the bones, liver, brain, and lungs. Bone metastases cause significant morbidity and mortality in late-stage breast c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60f29c20e9ecc0f24c38f1c54f6b6206
https://doi.org/10.1158/1538-7445.am2019-2007
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje